ArtiFascia® Brings Superior Sealing and Adherence Capabilities
FIRST HUMAN ARTIFASCIA STUDY – COMPLETED
INVESTIGATION TITLE: PROSPECTIVE, SINGLE-CENTER, NON-RANDOMIZED STUDY OF ARTIFASCIA®
IN SUBJECTS REQUIRING DURAL REPAIR FOLLOWING CRANIAL SURGERY
Primary endpoint: CSF leakage and patient safety
Summary of results: CSF leakage was not observed. No device-related adverse event was observed.
NEOART PIVOTAL STUDY – RECRUITING
A PROSPECTIVE, RANDOMIZED, CONTRLLED MULTI-CENTER STUDY OF ARTIFASCIA® DURAL REPAIR
PATCH COMPARED WITH COMMERCIALLY AVAILABLE DURAL SUBSTITUTES
Burst Strength of ArtiFascia®
vs Inter Cranial Pressure
Suture Retention Strength of ArtiFascia® vs. Collagen Patch
Tensile Strength of ArtiFascia®
vs. Collagen Patch
Adhesive Strength of ArtiFascia® vs. Collagen Patch
Sealing features of ArtiFascia® vs. Collagen Patch
Nurami Medical Nanofiber Technology © Copyright 2019
Designed & Created by Chen Ayala
Serves as Chairman of the of Department of
Neurosurgery at the Hannover Medical University Hospital, and Head of the
Commission for Technical Standards of the German Society of Neurosurgery, Secretary
of the European Society of Functional and Stereotactic Neurosurgery, and as Vice-
President of the World Society of Functional and Stereotactic Neurosurgery.
Agnesa Sharaev has 10 years’ experience in process development engineering and
production management in the biotechnology field. Among her expertise are development of
bio-material scaffolds for tissue engineering, leading engineering processes such as
scaling-up and technology transfer.. Agnesa is responsible for process development and
production management. Agnesa holds a B.Sc in Biotechnology Engineering from the Ort-
Braude college and certified as Quality Engineer from the Technion.